title: The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.
abstract: In pharmacoeconomics the costs and consequences of alternative medications are compared. Many countries have begun to use pharmacoeconomic evidence to support decisions on licensing, pricing, reimbursement, or addition to the formulary. In Saudi Arabia, it is not mandatory to submit cost effectiveness evidence to support licensing or addition to the formulary decisions however, data will be considered if submitted. Previous evidence suggests that the use of pharmacoeconomic evidence by Saudi Pharmacy and Therapeutic (P&T) committee members in formulary decisions making process is limited mainly because of lack of expertise and lack of resources. This paper intended to provide Saudi P&T decision makers with a clear set of best practice methodological recommendations to help in increasing the utilisation of pharmacoeconomic evidence in the formulary decisions making process.
authors: Pharmacoeconomics Research Unit, Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
authors: Sinaa A
authors: SA
authors: Al Aqeel
authors: Mohammed
authors: M
authors: Al-Sultan
references: Pharmacoeconomics. 2008;26(9):781-98
references: 18767898
references: Stat Methods Med Res. 2002 Dec;11(6):455-68
references: 12516984
references: Pharmacoeconomics. 2004;22(13):857-76
references: 15329031
references: BMJ. 2009 Jul 22;339:b2688
references: 22128393
references: Pharmacoeconomics. 2008;26(6):477-95
references: 18489199
references: J Med Econ. 2008;11(4):651-70
references: 19450074
references: Ann Intern Med. 1996 Oct 1;125(7):605-13
references: 8815760
references: J Med Econ. 2011;14(3):299-304
references: 21488712
references: Value Health. 2010 Mar-Apr;13(2):188-95
references: 19883407
references: Saudi Pharm J. 2011 Jan;19(1):51-6
references: 23960742
references: Infection. 2009 Apr;37(2):123-32
references: 19277465
references: Pharmacoeconomics. 2008;26(9):745-51
references: 18767895
references: Med Decis Making. 1996 Jul-Sep;16(3):288-99
references: 8818128
references: Value Health. 2011 Sep-Oct;14(6):846-51
references: 21914504
references: Value Health. 2001 May-Jun;4(3):225-50
references: 11705185
references: BMJ. 2004 Oct 23;329(7472):972-5
references: 15499118
references: BMJ. 2011 Aug 15;343:d5160
references: 21844159
references: Eur J Health Econ. 2009 Oct;10(4):357-9
references: 19618224
references: Pharmacoeconomics. 2009;27(9):767-79
references: 19757870
references: Pharmacoeconomics. 2008;26(9):769-79
references: 18767897
references: Value Health. 2010 Jan-Feb;13(1):28-33
references: 19883403
references: Lancet. 2002 May 18;359(9319):1771-4
references: 12049884
references: Value Health. 2009 Jun;12(4):409-18
references: 19900249
references: BMJ. 1999 Apr 24;318(7191):1136
references: 10213735
references: Pharmacoeconomics. 2004;22(14):929-42
references: 15362929
references: Value Health. 2005 Jan-Feb;8(1):10-23
references: 15841890
references: Value Health. 2003 Jan-Feb;6(1):9-17
references: 12535234
references: Res Social Adm Pharm. 2010 Sep;6(3):246-56
references: 20813337
references: Value Health. 2007 Sep-Oct;10(5):336-47
references: 17888098
references: Health Econ. 1996 Jul-Aug;5(4):279-96
references: 8880165
references: Pharmacoeconomics. 2006;24(4):355-71
references: 16605282